Cargando…

Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth

BACKGROUND: Stimulation of β(2)‐adrenoceptors can promote muscle hypertrophy and fibre type shift, and it can counteract atrophy and weakness. The underlying mechanisms remain elusive. METHODS: Fed wild type (WT), 2‐day fasted WT, muscle‐specific insulin (INS) receptor (IR) knockout (M‐IR(−/−)), and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonçalves, Dawit A., Silveira, Wilian A., Manfredi, Leandro H., Graça, Flávia A., Armani, Andrea, Bertaggia, Enrico, O´Neill, Brian T., Lautherbach, Natalia, Machado, Juliano, Nogara, Leonardo, Pereira, Marcelo G., Arcidiacono, Diletta, Realdon, Stefano, Kahn, C. Ronald, Sandri, Marco, Kettelhut, Isis C., Navegantes, Luiz Carlos C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463755/
https://www.ncbi.nlm.nih.gov/pubmed/30932373
http://dx.doi.org/10.1002/jcsm.12395
_version_ 1783410806917955584
author Gonçalves, Dawit A.
Silveira, Wilian A.
Manfredi, Leandro H.
Graça, Flávia A.
Armani, Andrea
Bertaggia, Enrico
O´Neill, Brian T.
Lautherbach, Natalia
Machado, Juliano
Nogara, Leonardo
Pereira, Marcelo G.
Arcidiacono, Diletta
Realdon, Stefano
Kahn, C. Ronald
Sandri, Marco
Kettelhut, Isis C.
Navegantes, Luiz Carlos C.
author_facet Gonçalves, Dawit A.
Silveira, Wilian A.
Manfredi, Leandro H.
Graça, Flávia A.
Armani, Andrea
Bertaggia, Enrico
O´Neill, Brian T.
Lautherbach, Natalia
Machado, Juliano
Nogara, Leonardo
Pereira, Marcelo G.
Arcidiacono, Diletta
Realdon, Stefano
Kahn, C. Ronald
Sandri, Marco
Kettelhut, Isis C.
Navegantes, Luiz Carlos C.
author_sort Gonçalves, Dawit A.
collection PubMed
description BACKGROUND: Stimulation of β(2)‐adrenoceptors can promote muscle hypertrophy and fibre type shift, and it can counteract atrophy and weakness. The underlying mechanisms remain elusive. METHODS: Fed wild type (WT), 2‐day fasted WT, muscle‐specific insulin (INS) receptor (IR) knockout (M‐IR(−/−)), and MKR mice were studied with regard to acute effects of the β(2)‐agonist formoterol (FOR) on protein metabolism and signalling events. MKR mice express a dominant negative IGF1 receptor, which blocks both INS/IGF1 signalling. All received one injection of FOR (300 μg kg(−1) subcutaneously) or saline. Skeletal muscles and serum samples were analysed from 30 to 240 min. For the study of chronic effects of FOR on muscle plasticity and function as well as intracellular signalling pathways, fed WT and MKR mice were treated with formoterol (300 μg kg(−1) day(−1)) for 30 days. RESULTS: In fed and fasted mice, one injection of FOR inhibited autophagosome formation (LC3‐II content, 65%, P ≤ 0.05) that was paralleled by an increase in serum INS levels (4‐fold to 25‐fold, P ≤ 0.05) and the phosphorylation of Akt (4.4‐fold to 6.5‐fold, P ≤ 0.05) and ERK1/2 (50% to two‐fold, P ≤ 0.05). This led to the suppression (40–70%, P ≤ 0.05) of the master regulators of atrophy, FoxOs, and the mRNA levels of their target genes. FOR enhanced (41%, P ≤ 0.05) protein synthesis only in fed condition and stimulated (4.4‐fold to 35‐fold, P ≤ 0.05) the prosynthetic Akt/mTOR/p70S6K pathway in both fed and fasted states. FOR effects on Akt signalling during fasting were blunted in both M‐IR(−/−) and MKR mice. Inhibition of proteolysis markers by FOR was prevented only in MKR mice. Blockade of PI3K/Akt axis and mTORC1, but not ERK1/2, in fasted mice also suppressed the acute FOR effects on proteolysis and autophagy. Chronic stimulation of β(2)‐adrenoceptors in fed WT mice increased body (11%, P ≤ 0.05) and muscle (15%, P ≤ 0.05) growth and downregulated atrophy‐related genes (30–40%, P ≤ 0.05), but these effects were abolished in MKR mice. Increases in muscle force caused by FOR (WT, 24%, P ≤ 0.05) were only partially impaired in MKR mice (12%, P ≤ 0.05), and FOR‐induced slow‐to‐fast fibre type shift was not blocked at all in these animals. In MKR mice, FOR also restored the lower levels of muscle SDH activity to basal WT values and caused a marked reduction (57%, P ≤ 0.05) in the number of centrally nucleated fibers. CONCLUSIONS: NS/IGF1 signalling is necessary for the anti‐proteolytic and hypertrophic effects of in vivo β(2)‐adrenergic stimulation and appears to mediate FOR‐induced enhancement of protein synthesis. INS/IGF1 signalling only partially contributes to gain in strength and does not mediate fibre type transition induced by FOR.
format Online
Article
Text
id pubmed-6463755
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64637552019-04-22 Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth Gonçalves, Dawit A. Silveira, Wilian A. Manfredi, Leandro H. Graça, Flávia A. Armani, Andrea Bertaggia, Enrico O´Neill, Brian T. Lautherbach, Natalia Machado, Juliano Nogara, Leonardo Pereira, Marcelo G. Arcidiacono, Diletta Realdon, Stefano Kahn, C. Ronald Sandri, Marco Kettelhut, Isis C. Navegantes, Luiz Carlos C. J Cachexia Sarcopenia Muscle Original Articles BACKGROUND: Stimulation of β(2)‐adrenoceptors can promote muscle hypertrophy and fibre type shift, and it can counteract atrophy and weakness. The underlying mechanisms remain elusive. METHODS: Fed wild type (WT), 2‐day fasted WT, muscle‐specific insulin (INS) receptor (IR) knockout (M‐IR(−/−)), and MKR mice were studied with regard to acute effects of the β(2)‐agonist formoterol (FOR) on protein metabolism and signalling events. MKR mice express a dominant negative IGF1 receptor, which blocks both INS/IGF1 signalling. All received one injection of FOR (300 μg kg(−1) subcutaneously) or saline. Skeletal muscles and serum samples were analysed from 30 to 240 min. For the study of chronic effects of FOR on muscle plasticity and function as well as intracellular signalling pathways, fed WT and MKR mice were treated with formoterol (300 μg kg(−1) day(−1)) for 30 days. RESULTS: In fed and fasted mice, one injection of FOR inhibited autophagosome formation (LC3‐II content, 65%, P ≤ 0.05) that was paralleled by an increase in serum INS levels (4‐fold to 25‐fold, P ≤ 0.05) and the phosphorylation of Akt (4.4‐fold to 6.5‐fold, P ≤ 0.05) and ERK1/2 (50% to two‐fold, P ≤ 0.05). This led to the suppression (40–70%, P ≤ 0.05) of the master regulators of atrophy, FoxOs, and the mRNA levels of their target genes. FOR enhanced (41%, P ≤ 0.05) protein synthesis only in fed condition and stimulated (4.4‐fold to 35‐fold, P ≤ 0.05) the prosynthetic Akt/mTOR/p70S6K pathway in both fed and fasted states. FOR effects on Akt signalling during fasting were blunted in both M‐IR(−/−) and MKR mice. Inhibition of proteolysis markers by FOR was prevented only in MKR mice. Blockade of PI3K/Akt axis and mTORC1, but not ERK1/2, in fasted mice also suppressed the acute FOR effects on proteolysis and autophagy. Chronic stimulation of β(2)‐adrenoceptors in fed WT mice increased body (11%, P ≤ 0.05) and muscle (15%, P ≤ 0.05) growth and downregulated atrophy‐related genes (30–40%, P ≤ 0.05), but these effects were abolished in MKR mice. Increases in muscle force caused by FOR (WT, 24%, P ≤ 0.05) were only partially impaired in MKR mice (12%, P ≤ 0.05), and FOR‐induced slow‐to‐fast fibre type shift was not blocked at all in these animals. In MKR mice, FOR also restored the lower levels of muscle SDH activity to basal WT values and caused a marked reduction (57%, P ≤ 0.05) in the number of centrally nucleated fibers. CONCLUSIONS: NS/IGF1 signalling is necessary for the anti‐proteolytic and hypertrophic effects of in vivo β(2)‐adrenergic stimulation and appears to mediate FOR‐induced enhancement of protein synthesis. INS/IGF1 signalling only partially contributes to gain in strength and does not mediate fibre type transition induced by FOR. John Wiley and Sons Inc. 2019-04-01 2019-04 /pmc/articles/PMC6463755/ /pubmed/30932373 http://dx.doi.org/10.1002/jcsm.12395 Text en © 2019 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Gonçalves, Dawit A.
Silveira, Wilian A.
Manfredi, Leandro H.
Graça, Flávia A.
Armani, Andrea
Bertaggia, Enrico
O´Neill, Brian T.
Lautherbach, Natalia
Machado, Juliano
Nogara, Leonardo
Pereira, Marcelo G.
Arcidiacono, Diletta
Realdon, Stefano
Kahn, C. Ronald
Sandri, Marco
Kettelhut, Isis C.
Navegantes, Luiz Carlos C.
Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth
title Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth
title_full Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth
title_fullStr Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth
title_full_unstemmed Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth
title_short Insulin/IGF1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth
title_sort insulin/igf1 signalling mediates the effects of β(2)‐adrenergic agonist on muscle proteostasis and growth
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463755/
https://www.ncbi.nlm.nih.gov/pubmed/30932373
http://dx.doi.org/10.1002/jcsm.12395
work_keys_str_mv AT goncalvesdawita insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT silveirawiliana insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT manfredileandroh insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT gracaflaviaa insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT armaniandrea insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT bertaggiaenrico insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT oneillbriant insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT lautherbachnatalia insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT machadojuliano insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT nogaraleonardo insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT pereiramarcelog insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT arcidiaconodiletta insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT realdonstefano insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT kahncronald insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT sandrimarco insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT kettelhutisisc insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth
AT navegantesluizcarlosc insulinigf1signallingmediatestheeffectsofb2adrenergicagonistonmuscleproteostasisandgrowth